Raytheon Technologies Corp vs Tilray Brands Inc — how do they compare? Raytheon Technologies Corp trades at $185.73 (market cap $248.42B), while Tilray Brands Inc trades at $3.52 (market cap $530.54M). The key difference: Raytheon Technologies Corp is far larger — about 468.2× Tilray Brands Inc's market cap, and Raytheon Technologies Corp pays a 1.58% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| RTX | TLRY | |
|---|---|---|
Market Cap | $248.42B | $530.54M |
Volume | 4,380,368 | 9,099,075 |
Sector | Industrials | Health |
52-Week High | $225.49 | $21.00 |
52-Week Low | $157.00 | $3.57 |
Enterprise Value | $278.97B | $684.46M |
Dividend Yield | 1.58% | — |
Typical Hold Time | — | 31 Days |
Signals from Pluang's Aura AI — not financial advice
RTX trades at $180.26, down 1.65% today, amid a bearish technical signal but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q3 2026 EPS expected at $1.77. Revenue grew to $88.6B in 2025, with net income margin improving to 7.59%. Analyst consensus remains strongly bullish with a $236.27 price target and 65% buy ratings, supported by a $289B backlog and defense sector tailwinds.
The outlook for RTX is positive given robust defense spending, earnings momentum, and analyst confidence. Risks include execution on large contracts, debt levels, and geopolitical uncertainties. The stock offers growth potential with a 30% upside to consensus target, but investors should monitor quarterly execution and defense budget developments.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →